Check this video on what we do.
MabSwitch is advancing a multi-product, multi-modality clinical pipeline with a focus on developing First and/or Best in class next-generation antibody therapeutic candidates.
Download poster presented at Festival of Biologics, San Diego, April 2024
Therapeutic Pipeline
We liberate therapeutic antibodies from the usual constraints of a fixed functional profile.
Switches can improve safety of bi- or multispecific antibodies with longer plasma half life.
Matching CAR-T cell activity in-vivo with tumor loads or controlling inflammatory side effects is only the start.
Adding an affinity switch to silence or boost long half-life drug function in real time in the patient allows re-thinking of many therapeutic concepts.
Our lead program, an anti-CD19 Switchable Affinity CAR (SaefCAR) T-Cell therapy, supported by the National Cancer Institute (NCI), is positioned as a potential best-in-class CAR-T therapy for autoimmune diseases and B cell cancers.
Additionally, we are developing switchable affinity T-cell engagers (SaefTE) and antibody drug conjugates (SaefADC). Another active project is our switchable affinity (mild-elution) immunoaffinity ligand (SAFE Ligands) for high-yield purification of Lentiviral vectors, supported by the National Center for Advancing Translational Sciences (NCATS), which is now progressing toward product optimization